
DATE: 23 April 2014

CONTEXT AND POLICY ISSUES

Nausea and vomiting are two of the most severe and distressing side effects in patients receiving chemotherapeutic drugs for cancer treatment. Previous studies have indicated that at least 90% of patients receiving highly emetogenic chemotherapeutics such as cisplatin and paclitaxel suffer emesis if prophylactic antiemetics are not provided. Inadequate control of nausea and vomiting in these patients may lead to reduced nutritional status, impaired health-related quality of life, or reduce adherence to treatment. Postoperative nausea and vomiting (PONV) are common adverse events following surgery and anaesthesia, and also a frequent cause of unplanned readmission in ambulatory surgery. Serotonin receptor antagonists (5-HT3RAs) are one of the most widely used pharmacological therapy for chemotherapy-induced nausea and vomiting (CINV). First generation 5-HT3RAs agents, including ondansetron, granisetron and dolasetron, in combination with a corticosteroid plus or minus a neurokinin-1 inhibitor, have been the standard of care for acute CINV prevention. The clinical effectiveness of 5-HT3RAs agents in preventing PONV has been demonstrated in clinical trials as well.

Ondansetron has been approved by Health Canada in preventing CINV from both moderately and highly emetogenic chemotherapy in adults and children 4 to 12 years of age, or PONV in adults younger than 65 years of age. In these patients, ondansetron is suggested to be administered up to 5 days after chemotherapy or radiotherapy, and one single dose of ondansetron is recommended in prevention of PONV. Granisetron is indicated for prevention of CINV and radiation-induced nausea and vomiting in adults. It is administered as one single dose before initiation of chemotherapy only, or a divided dose before chemotherapy followed by a second dose 12 hours post-chemotherapy on the day when chemotherapy is given. Granisetron is not indicated for prevention or treatment of PONV. Dolasetron tablets for oral use can be used to prevent CINV in adults; however they are contraindicated for PONV. In 2011, Health Canada issued an alert that the injectable form of dolasetron should no longer be used to prevent CINV due to potential risk of arrhythmias.

Effectiveness and safety of longer-term uses of ondansetron and granisetron have been

Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations. The information included in this response is not intended to replace professional medical advice, nor should it be construed as a recommendation for or against the use of a particular health technology. Readers are also cautioned that a lack of good quality evidence does not necessarily mean a lack of effectiveness particularly in the case of new and emerging health technologies, for which little information can be found, but which may in future prove to be effective. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete and up to date, CADTH does not make any guarantee to that effect. CADTH is not liable for any loss or damages resulting from use of the information in the report.

Copyright: This report contains CADTH copyright material and may contain material in which a third party owns copyright. This report may be used for the purposes of research or private study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner.

Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions.
investigated in randomized controlled trials (RCTs) enrolling patients with conditions other than nausea and vomiting, such as alcohol dependence, stable schizophrenia, and tinnitus. Treatment durations ranged from 4 to 12 weeks. Treatment with these 5-HT3RAs agents was not related with higher risk of adverse events, although patients were more likely to report constipation than placebo. No serious adverse events were reported in these RCTs.

The purpose of this review is to provide evidence on the comparative clinical effectiveness and safety of the long-term use (> 5 days) of 5-HT3RAs for the prevention of nausea and vomiting.

**RESEARCH QUESTIONS**

1. What is the clinical effectiveness of the long-term use (> 5 days) of ondansetron, dolasetron, and granisetron for the prevention of nausea and vomiting?

2. What is the clinical evidence on the safety and harms of the long-term use (> 5 days) of ondansetron, dolasetron, and granisetron for the prevention of nausea and vomiting?

**KEY FINDINGS**

No evidence regarding the efficacy and safety of the long-term use of 5-HT3RAs in preventing nausea and vomiting was identified.

**METHODS**

**Literature Search Strategy**

A limited literature search was conducted on key resources including PubMed, The Cochrane Library (2014, Issue 3), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2009 and March 24, 2014.

**Selection Criteria and Methods**

One reviewer screened the titles and abstracts of the retrieved publications and evaluated the full-text publications for the final article selection, according to the selection criteria present in Table 1.

**Table 1: Selection Criteria**

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients requiring anti-emetic therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention</strong></td>
<td>Long-term use (&gt; 5 days) of the following 5-HT3RAs: Ondansetron, granisetron or dolasetron</td>
</tr>
<tr>
<td><strong>Comparator</strong></td>
<td>Other 5-HT3RAs</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
</tr>
<tr>
<td></td>
<td>No comparator</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Decrease in nausea and vomiting</td>
</tr>
<tr>
<td></td>
<td>Health-related quality of life</td>
</tr>
<tr>
<td></td>
<td>Safety</td>
</tr>
</tbody>
</table>
Study Designs

| Study Designs | Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, and non-randomized studies |

5-HT3RA=5-hydroxytryptamine3 receptor antagonist

Exclusion Criteria

Studies were excluded if they did not meet the selection criteria in Table 1, were published prior to 2009, or duplicate publications of the same study. Studies reporting short-term (≤ 5 days) use of 5-HT3RA or not specifying treatment duration were excluded.

SUMMARY OF EVIDENCE

Quantity of Research Available

The literature search yielded 560 citations. Upon screening titles and abstracts, 544 citations were excluded, and 16 potentially relevant articles were retrieved for full-text review. Of the 16 potentially relevant reports, none of them met the inclusion criteria. The process of study selection is outlined in the PRISMA flowchart (Appendix 1).

Additional references of potential interest are provided in Appendix 2.

CONCLUSIONS AND IMPLICATIONS FOR DECISION OR POLICY MAKING

The research questions regarding the clinical efficacy and safety of long-term use of ondansetron, granisetron and dolasetron for preventing nausea and vomiting cannot be answered, as no evidence published within the search timeframe was identified.

PREPARED BY:
Canadian Agency for Drugs and Technologies in Health
Tel: 1-866-898-8439
www.cadth.ca
## REFERENCES


APPENDIX 1: Selection of Included Studies

560 citations identified from electronic literature search and screened

544 citations excluded

16 potentially relevant articles retrieved for scrutiny (full text, if available)

16 potentially relevant reports retrieved from other sources (grey literature, hand search)

16 potentially relevant reports

16 reports excluded:
- irrelevant intervention (13)
- irrelevant study design (3)

0 reports included in review
APPENDIX 2: Additional References of Potential Interest

Not a systematic review